Korean J Helicobacter Up Gastrointest Res.
2024 Jun;24(2):100-102. 10.7704/kjhugr.2024.0023.
Current Status and Future Perspectives of Tegoprazan-Based Helicobacter pylori Eradication Therapy
- Affiliations
-
- 1Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
- KMID: 2556441
- DOI: http://doi.org/10.7704/kjhugr.2024.0023
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
- Comparison of Tegoprazan- and Lansoprazole-Based Fourteen-Day Triple Therapies as First-Line Treatments for Helicobacter pylori Eradication
- Potassium-competitive Acid Blockers: A New Therapeutic Strategy for Helicobacter pylori Eradication
- Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
- Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
